|
SAN
DIEGO, March 8 /PRNewswire-FirstCall/ -- Nanogen,
Inc. (Nasdaq: NGEN), developer of advanced diagnostic
products, announced today its subsidiary SynX signed
five new European distributors for its point-of-care
products. The additional distribution agreements significantly
increase SynX's coverage to 28 European nations. All
of SynX's European distributors were selected based
on prior experience in the point-of-care medical device
and equipment sector, as well as knowledge with cardiac
and central nervous system diseases. Each partner
will be responsible for the distribution and marketing
of SynX's point-of-care tests and research oriented
products for congestive heart failure (CHF) and myocardial
infarction. Expected to be commercially available
in 2005, the CHF diagnostic product will measure NT-proBNP
(N-terminal pro-hormone brain natriuretic peptide),
a sensitive and specific biomarker for the diagnosis
of congestive heart failure. "These new distribution
partners complement our existing distributor networks
and provide us with significant relationships with
point-of-care diagnostic decision makers in the hospital
and research market segments," said Howard C.
Birndorf, Nanogen's chairman of the board and chief
executive officer. "Development of our congestive
heart failure test is progressing and expansion of
our distribution network is a key objective that will
be important to the success of the product."
The newly expanded network
provides SynX with exposure to a potential customer
base of over 7,500 hospitals, 4,000 clinical laboratories
and almost 11,000 cardiac specialists as measured
by the European Diagnostic Manufacturers Association,
excluding the newly emerging EU nations.
About Nanogen, Inc.
Nanogen's advanced diagnostics
provide physicians and patients worldwide with sophisticated
information to predict, diagnose and treat disease.
Research and clinical reference labs use the highly
accurate and reliable NanoChip(R) Molecular Biology
Workstation, NanoChip(R) Electronic Microarray and
broad suite of analyte specific reagents to develop
tests to detect infectious diseases, drug toxicity
and mutations associated with cancer, cardiovascular
and genetic diseases. The next generation instrument
system, the NanoChip(R) 400, is expected to be available
in 2005. Nanogen's subsidiary SynX offers a line of
point-of-care diagnostic tests and is building expertise
in cardiac related health conditions. Nanogen's ten
years of pioneering research involving nanotechnology
may also have future applications in medical diagnostics,
biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
.
SOURCE Nanogen, Inc.
CONTACT: Robert Saltmarsh, Chief Financial Officer
of Nanogen, Inc., +1-
858-410-4600; or Pam Lord of Atkins + Associates,
Media & Investor Relations,
+1-858-527-3494, plord@irpr.com, for Nanogen, Inc./
/Web site: http://www.nanogen.com/
|
